Ferring Pharmaceuticals

27 total trials 4 currently recruiting 23 completed

Trial Pipeline

RECRUITING Phase 1

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

NCT06668493

RECRUITING Phase 3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374

RECRUITING Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955

RECRUITING Phase 1

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

NCT04113382

COMPLETED Phase 1

A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

NCT05924321

COMPLETED Phase 3

Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)

NCT04163458

COMPLETED Phase 3

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

NCT02522780

COMPLETED Phase 1

Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy

NCT01928862

COMPLETED Phase 3

LutrePulse Hypogonadotropic Hypogonadism

NCT01976728

COMPLETED Phase 3

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel

NCT01665599

COMPLETED Phase 3

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

NCT01552343

COMPLETED Phase 2

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

NCT01491971

COMPLETED Phase 2

A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator

NCT01464879

COMPLETED Phase 4

Menopur Mixed Protocol

NCT01417195

COMPLETED Phase 2

Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)

NCT01283022

COMPLETED Phase 3

Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

NCT01127581

COMPLETED Phase 3

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep

NCT01073930

COMPLETED Phase 2

Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy

NCT00925938

COMPLETED Phase 1

Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)

NCT00950105

COMPLETED Phase 2

Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor

NCT00828711

COMPLETED Phase 3

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

NCT00615836

COMPLETED Phase 3

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

NCT00477490

COMPLETED Phase 3

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

NCT01280981

COMPLETED Phase 3

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

NCT00451958

COMPLETED Phase 2

Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC

NCT00423371

COMPLETED Phase 3

Efficacy and Safety Study of XP12B in Women With Menorrhagia

NCT00386308

COMPLETED Phase 3

Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor

NCT00308711

What the Pipeline for Ferring Pharmaceuticals Shows

According to the ClinicalTrials.gov registry, Ferring Pharmaceuticals is linked to 27 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 15% of the sponsor's indexed portfolio — and 23 are already marked complete, representing roughly 85% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Ferring Pharmaceuticals reports 16 late-stage studies (Phase 3 and Phase 4 combined) and 11 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Ferring Pharmaceuticals is Cervical Ripening with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial